Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.
Theresa-Marie DachsFranz DucaRené RettlChristina Binder-RodriguezDaniel DalosLuciana Camuz LigiosAndreas Anselm KammerlanderEkkehard GrünigIngrid PretschRegina Steringer-MascherbauerKlemens AblasserManfred WargenauJulia MascherbauerIrene M LangChristian HengstenbergRoza Badr-EslamJohannes KastnerDiana BondermanPublished in: European heart journal (2022)
The vasodilator riociguat improved haemodynamics in PH-HFpEF. Riociguat was safe in most patients but led to more dropouts as compared to placebo and did not change clinical symptoms within the study period.